Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(4 sites)

United States

University of California Los Angeles, Los Angeles, California

University of Florida, Gainesville, Florida

New York Medical College, Valhalla, New York

Medical College of Wisconsin, Milwaukee, Wisconsin